Where can you check a GHK-Cu finding?

How to trace a GHK-Cu claim back to its paper

After each study claim you'll see a number inside square brackets. Look for that number in the list below. It gives the paper's title and a public web address where you can read it. The paper says what was tested, on whom, and for how long.

The oldest paper is a 1988 study of skin cells ^[1]. Broad reviews by Loren Pickart come next ^[2][6]. The newest, from 2024-2025, cover wrinkles, sore colons and brain cells ^[13][14][15]. Those papers also back the wound research page and the safety questions.

Be careful with the broadest claims. Much of the early wound and gene work came from Pickart, who lived 1938-2023, and his co-workers ^[2][6]. Many of those claims still haven't been repeated by an outside team. The big gene finding came from a computer search of earlier lab results on human cells. Nobody was treated ^[2].

Other teams tested lung cells ^[9], mice with scarred lungs ^[8], mice with sore colons ^[14] and brain cells ^[15]. Outside checks help, but an animal or dish result still isn't proof for people like you.

Why none of these papers makes GHK-Cu an approved drug

A paper reports a test. Approval comes from a government drug agency, after much bigger trials. FDA hasn't approved GHK-Cu for any treatment, in any form. Europe's drug agency hasn't either. EMA is its short name. Skin creams may legally list Copper Tripeptide-1. Pills, shots and other whole-body forms have no approval ^[6].

A skin-wound trial called CuHeal has been entered on the public list of planned trials. A listing only shows it was planned, and the source doesn't say whether it has begun or finished. No finished Phase 2/3 trial covers shots or whole-body use. Those are the larger trials that test whether a drug works and what harm it causes.